Listing of Claims:

1. (Currently amended) A follicle stimulating hormone peptide conjugate comprising at least one ~~the~~ moiety having the formula:



wherein

D is a member selected from -OH and R^1-L-HN-;

G is a member selected from R^1-L- and -C(O)(C_1-C_6)alkyl;

R^1 is a moiety comprising a member selected a moiety comprising a straight-chain or branched poly(ethylene glycol) residue; and

L is a linker which is a member selected from a bond, substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl,

such that when D is OH, G is R^1-L-, and when G is –C(O)(C_1-C_6)alkyl, D is R^1-L-NH-.

2. (Currently amended) The peptide conjugate according to claim 1, wherein R^1-L ~~L-R~~^{1} has the formula:



wherein

a is an integer from 0 to 20.

3. (Currently amended) The peptide conjugate according to claim 1, wherein R^1 has a structure that is a member selected from:



;





; and



wherein

e and f are integers independently selected from 1 to 2500; and

q is an integer from 0 to 20.

4. (Currently amended) The peptide conjugate according to claim 1, wherein R^1 has a structure that is a member selected from:



;



;



; and



wherein

e, f and f' are integers independently selected from 1 to 2500; and

q and q' are integers independently selected from 1 to 20.

5. (Currently amended) The peptide conjugate according to claim 1, wherein R^1 has a structure that is a member selected from:



; and



wherein

e, f and f' are integers independently selected from 1 to 2500; and

q, q' and q"are integers independently selected from 1 to 20.

6. (Currently amended) The peptide conjugate according to claim 1, wherein R^1 has a structure that is a member selected from:



; and



wherein

e and f are integers independently selected from 1 to 2500.

7. (Currently amended) The ~~FSH~~ peptide conjugate according to claim 1, wherein said moiety has the formula:



8. (Currently amended) The peptide conjugate according to claim 1, wherein said peptide has an amino acid sequence selected from SEQ[.] ID[.] NO:1 and SEQ ID NO:2.

9. (Currently amended) The ~~FSH~~ peptide conjugate according to claim **1**, wherein said moiety has the formula:



wherein

a, b, c, d, i, r, s, t, and u are integers independently selected from 0 and 1;

q is 1;

e, f, g, and h are members independently selected from the integers from 0 to 6;

j, k, l, and m are members independently selected from the integers from 0 and 100;

v, w, x, and y are independently selected from 0 and 1, and least one of v, w, x and y is 1;

AA is an amino acid residue of said FSH peptide;

Sia-(R) has the formula:



~~wherein~~

~~D is a member selected from -OH and R^1-L-HN-;~~

~~G is a member selected from R^1-L- and -C(O)(C_1-C_6)alkyl;~~

~~R^1 is a moiety comprising a member selected a straight chain or branched poly(ethylene glycol) residue; and~~

~~L is a linker which is a member selected from a bond, substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl,~~

~~such that when D is OH, G is R^1-L-, and when G is -C(O)(C_1-C_6)alkyl, D is R^1-L-NH-.~~

10. (Currently amended) The peptide conjugate according to claim 9, wherein said amino acid residue is an asparagine residue.

11. (Currently amended) The peptide conjugate according to claim 10, wherein said ~~said~~ amino acid residue is an asparagine residue ~~which is a member~~ selected from N7 of SEQ ID NO:2, N24 of SEQ ID NO:2, N52 of SEQ ID NO:1, and N78 of SEQ ID NO:1~~, and combinations thereof~~.

12. (Currently amended) The peptide conjugate according to claim 1, wherein said peptide is a bioactive follicle stimulating hormone peptide.

13. (Original) A method of making a FSH peptide conjugate comprising the moiety:



wherein

D is a member selected from -OH and R^1-L-HN-;

G is a member selected from R^1-L- and -C(O)(C_1-C_6)alkyl;

R^1 is a moiety comprising a member selected a straight-chain or branched poly(ethylene glycol) residue; and

L is a linker which is a member selected from a bond, substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl,

such that when D is OH, G is R^1-L-, and when G is $-C(O)(C_1-C_6)$alkyl, D is R^1-L-NH-,

said method comprising:

(a) contacting a substrate FSH peptide with a PEG-sialic acid donor moiety having the formula:



and an enzyme that transfers said PEG-sialic acid onto an amino acid or glycosyl residue of said FSH peptide, under conditions appropriate for the transfer.

14. (Currently amended) The method according to claim 13, wherein $\underline{R^1\text{-L}}$ ~~L-R$^+$~~ has the formula:



wherein

a is an integer from 0 to 20.

15. (Original) The method according to claim 13, wherein R^1 has a structure that is a member selected from:



;





; and



wherein

e and f are integers independently selected from 1 to 2500; and

q is an integer from 0 to 20.

16. (Original) The method according to claim 13, wherein R^1 has a structure that is a member selected from:



;



;



; and



wherein

e, f and f' are integers independently selected from 1 to 2500; and

q and q' are integers independently selected from 1 to 20.

17. (Original) The method according to claim 13, wherein R^1 has a structure that is a member selected from:



; and



wherein

e, f and f' are integers independently selected from 1 to 2500; and

q, q' and q"are integers independently selected from 1 to 20.

18. (Original) The method according to claim 13, wherein R^1 has a structure that is a member selected from:



; and



wherein

e and f are integers independently selected from 1 to 2500.

19. (Original) The method of claim 13, further comprising, prior to step (a):

(b) expressing said substrate follicle stimulating hormone peptide in a suitable host.

20. (Original) The method of claim **13,** wherein said host is selected from an insect cell and a mammalian cell.

21. (Currently amended) A method of stimulating ovarian follicles in a mammal, said method comprising administering to said mammal the ~~a~~ peptide conjugate according to claim 1.

22. (Currently amended) A method of treating a condition in a subject in need thereof, said condition characterized by reproductive infertility said method comprising the step of administering to the subject an amount of the ~~a~~ peptide conjugate according to claim 1, effective to ameliorate said condition in said subject.

23. (Currently amended) A pharmaceutical formulation comprising the ~~follicle-stimulating hormone~~ peptide conjugate according to claim 1, and a pharmaceutically acceptable carrier.